TP53 and lymphoma: That the high sensitivity to CX-5461 was the consequence of the activation of p53 was demonstrated by the fact that Eμ-MYC lymphoma cells, with elevated basal rates of Pol I transcription, mutant or null for p53 exhibited a 180-fold decreased sensitivity to the drug [91].